175 related articles for article (PubMed ID: 29168654)
1. Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.
Havard R; Henry NL
Future Oncol; 2017 Dec; 13(28):2507-2510. PubMed ID: 29168654
[No Abstract] [Full Text] [Related]
2. The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Ethier JL; Amir E
Mol Diagn Ther; 2016 Aug; 20(4):307-13. PubMed ID: 27235162
[TBL] [Abstract][Full Text] [Related]
3. Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.
Ribnikar D; Bedard PL
Future Oncol; 2017 Dec; 13(30):2733-2736. PubMed ID: 29168649
[No Abstract] [Full Text] [Related]
4. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
[TBL] [Abstract][Full Text] [Related]
5. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
Kuijer A; Drukker CA; Elias SG; Smorenburg CH; Th Rutgers EJ; Siesling S; van Dalen T
Int J Cancer; 2016 Aug; 139(4):769-75. PubMed ID: 27062369
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer genomics: real-time use.
Bertucci F; Birnbaum D
Lancet Oncol; 2007 Dec; 8(12):1045-1047. PubMed ID: 18054870
[No Abstract] [Full Text] [Related]
7. Individualizing therapeutic decision making in early-stage breast cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):41-2. PubMed ID: 17824559
[No Abstract] [Full Text] [Related]
8. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
[TBL] [Abstract][Full Text] [Related]
9. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
10. First-generation genomic tests for breast cancer treatment.
Andre F; Delaloge S
Lancet Oncol; 2010 Jan; 11(1):6-7. PubMed ID: 20005177
[No Abstract] [Full Text] [Related]
11. Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
Savci-Heijink CD; Halfwerk H; Koster J; Van de Vijver MJ
BMC Cancer; 2017 Nov; 17(1):755. PubMed ID: 29132326
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX
Curtit E; Mansi L; Maisonnette-Escot Y; Sautière JL; Pivot X
Eur J Surg Oncol; 2017 May; 43(5):921-930. PubMed ID: 28087099
[TBL] [Abstract][Full Text] [Related]
13. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
[TBL] [Abstract][Full Text] [Related]
15. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Magbanua MJ; Wolf DM; Yau C; Davis SE; Crothers J; Au A; Haqq CM; Livasy C; Rugo HS; ; Esserman L; Park JW; van 't Veer LJ
Breast Cancer Res; 2015 May; 17(1):73. PubMed ID: 26021444
[TBL] [Abstract][Full Text] [Related]
16. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
17. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
[TBL] [Abstract][Full Text] [Related]
18. Online accounts of gene expression profiling in early-stage breast cancer: Interpreting genomic testing for chemotherapy decision making.
Ross E; Swallow J; Kerr A; Cunningham-Burley S
Health Expect; 2019 Feb; 22(1):74-82. PubMed ID: 30387238
[TBL] [Abstract][Full Text] [Related]
19. Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
Santa-Maria CA; Kruse M; Raska P; Weiss M; Swoboda A; Mutonga MB; Abraham J; Jain S; Nanda R; Montero AJ
Breast Cancer Res Treat; 2017 Nov; 166(1):179-184. PubMed ID: 28752189
[TBL] [Abstract][Full Text] [Related]
20. Integrating breast cancer genetics into clinical practice.
Mukherjee A; Rakha EA
Womens Health (Lond); 2012 Jan; 8(1):99-112. PubMed ID: 22171779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
